Bridgeway Capital Management’s Acrivon Therapeutics ACRV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $27.3K | Sell |
22,900
-55,000
| -71% | -$65.5K | ﹤0.01% | 1155 |
|
|
2025
Q1 | $158K | Buy |
77,900
+3,300
| +4% | +$6.7K | ﹤0.01% | 966 |
|
|
2024
Q4 | $449K | Sell |
74,600
-2,381
| -3% | -$14.3K | 0.01% | 841 |
|
|
2024
Q3 | $539K | Buy |
76,981
+18,800
| +32% | +$132K | 0.01% | 846 |
|
|
2024
Q2 | $337K | Hold |
58,181
| – | – | 0.01% | 948 |
|
|
2024
Q1 | $416K | Buy |
58,181
+26,200
| +82% | +$187K | 0.01% | 969 |
|
|
2023
Q4 | $157K | Buy |
+31,981
| New | +$157K | ﹤0.01% | 1180 |
|